Odyssey Therapeutics Acquisition | Healthcare Deal in NY

Odyssey Therapeutics has completed the acquisition of a pharmacy business in New York, for $279M. Odyssey Therapeutics is an immune-focused healthcare company developing medicines for autoimmune disorders, aligning with pharmacy acquisition strategies in NY acquisitions. The company’s IPO proceeds support continued clinical and commercial development of its immunology pipeline, supporting healthcare M&A and other acquisition activity. The deal is structured as an other acquisition tied to an announced $279 million initial public offering, with 15.5 million shares priced at $18 and an additional $25 million raised via a concurrent private stock sale. Odyssey Therapeutics is led by biotech executive Gary Glick and is expected to begin trading on Nasdaq under the ticker ODTX.